JP2011527704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527704A5 JP2011527704A5 JP2011517646A JP2011517646A JP2011527704A5 JP 2011527704 A5 JP2011527704 A5 JP 2011527704A5 JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011527704 A5 JP2011527704 A5 JP 2011527704A5
- Authority
- JP
- Japan
- Prior art keywords
- independent
- groups
- weight
- alkyl
- transcutol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 7
- -1 1,3-benzothiazolyl Chemical group 0.000 claims 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001806 thionaphthenyl group Chemical group 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/171,515 US8026271B2 (en) | 2008-07-11 | 2008-07-11 | Formulations of indol-3-yl-2-oxoacetamide compounds |
| US12/171,515 | 2008-07-11 | ||
| PCT/US2009/050210 WO2010006234A2 (en) | 2008-07-11 | 2009-07-10 | Anticancer oral formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527704A JP2011527704A (ja) | 2011-11-04 |
| JP2011527704A5 true JP2011527704A5 (cg-RX-API-DMAC7.html) | 2012-08-16 |
| JP5596680B2 JP5596680B2 (ja) | 2014-09-24 |
Family
ID=41505721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517646A Expired - Fee Related JP5596680B2 (ja) | 2008-07-11 | 2009-07-10 | 経口抗がん製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8026271B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2310363B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5596680B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101627382B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102159541B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2426599T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI384984B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010006234A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
| TW201602113A (zh) | 2009-06-29 | 2016-01-16 | 英塞特公司 | 作為ｐｉ３ｋ抑制劑之嘧啶酮 |
| WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| HRP20190867T1 (hr) | 2011-05-12 | 2019-07-12 | Proteostasis Therapeutics, Inc. | Regulatori proteostaze |
| SG10201912484RA (en) | 2011-09-02 | 2020-02-27 | Incyte Corp | Heterocyclylamines as pi3k inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| EP4183789A1 (en) | 2015-02-27 | 2023-05-24 | Incyte Holdings Corporation | Salts of pi3k inhibitor and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| CN119258070A (zh) | 2018-06-01 | 2025-01-07 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
| TWI323658B (en) * | 2001-12-06 | 2010-04-21 | Nat Health Research Institutes | Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same |
| BRPI0518484A2 (pt) * | 2004-11-24 | 2008-11-18 | Merck & Co Inc | composiÇço, cÁpsula, e, processo para preparar a mesma |
| US20060134204A1 (en) * | 2004-12-21 | 2006-06-22 | Wong Patrick S | Complexes made using low solubility drugs |
| TWI376239B (en) * | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| CA2669815A1 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| EP2476461A3 (en) * | 2007-01-16 | 2012-10-24 | BiPar Sciences, Inc. | Formulations For Cancer Treatment |
| US8026271B2 (en) | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
-
2008
- 2008-07-11 US US12/171,515 patent/US8026271B2/en not_active Expired - Fee Related
-
2009
- 2009-07-09 TW TW098123197A patent/TWI384984B/zh not_active IP Right Cessation
- 2009-07-10 EP EP09795224.6A patent/EP2310363B1/en not_active Not-in-force
- 2009-07-10 ES ES09795224T patent/ES2426599T3/es active Active
- 2009-07-10 WO PCT/US2009/050210 patent/WO2010006234A2/en not_active Ceased
- 2009-07-10 KR KR1020117003208A patent/KR101627382B1/ko not_active Expired - Fee Related
- 2009-07-10 CN CN200980126979.4A patent/CN102159541B/zh not_active Expired - Fee Related
- 2009-07-10 JP JP2011517646A patent/JP5596680B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527704A5 (cg-RX-API-DMAC7.html) | ||
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| CN101410098B (zh) | 包括含亲脂性药物的纳米胶囊的微球 | |
| CN103260741B (zh) | 本体肠溶胶囊壳 | |
| TW522012B (en) | Denaturants for sympathomimetic amine salts | |
| JP2010523553A5 (cg-RX-API-DMAC7.html) | ||
| JP2018058870A (ja) | 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル | |
| JP2012502037A5 (cg-RX-API-DMAC7.html) | ||
| JP2015503593A5 (cg-RX-API-DMAC7.html) | ||
| CN100500137C (zh) | 用于片剂和囊片的膜包衣 | |
| CN1446083A (zh) | 具有活性物质可控性释放的涂覆药物剂型 | |
| JP2023052045A (ja) | 重水素化ドンペリドン組成物、方法、及び調製 | |
| JP2011225600A5 (cg-RX-API-DMAC7.html) | ||
| Yang et al. | Curcumin-loaded gelatin nanoparticles cross the blood-brain barrier to treat ischemic stroke by attenuating oxidative stress and neuroinflammation | |
| JP2019526537A5 (cg-RX-API-DMAC7.html) | ||
| JP2014534196A5 (cg-RX-API-DMAC7.html) | ||
| JP2007537258A5 (cg-RX-API-DMAC7.html) | ||
| JP2011088926A5 (cg-RX-API-DMAC7.html) | ||
| RU2014149010A (ru) | Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина | |
| JP2007526238A5 (cg-RX-API-DMAC7.html) | ||
| JP2009544665A5 (cg-RX-API-DMAC7.html) | ||
| CN1759829A (zh) | 一种度洛西汀肠溶微丸胶囊及其制备方法 | |
| JP2011046708A5 (cg-RX-API-DMAC7.html) | ||
| Shahid et al. | pH-Responsive nanocomposite based hydrogels for the controlled delivery of ticagrelor; in vitro and in vivo approaches | |
| JP2007505105A5 (cg-RX-API-DMAC7.html) |